Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05066178 · ClinicalTrials.gov registry record · NA

Speech Treatment for Minimally Verbal Children With ASD and CAS

A NA study of Autism Spectrum Disorder and Developmental Verbal Dyspraxia, sponsored by MGH Institute of Health Professions.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT05066178 is a NA study of Autism Spectrum Disorder and Developmental Verbal Dyspraxia that is actively recruiting participants, run by MGH Institute of Health Professions. The registered enrollment target is 20 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05066178, a NA study of Autism Spectrum Disorder and Developmental Verbal Dyspraxia, is actively recruiting participants, sponsored by MGH Institute of Health Professions.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.

Interventions

  • BEHAVIORAL CAS Treatment for Minimally Verbal Children with Autism

Study Locations (1)

Massachusetts

  • MGH Institute of Health Professions - Boston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-05-01
Est. Completion 2026-11-30
Phase NA

What the Registry Record Tells You About NCT05066178

The ClinicalTrials.gov registry entry for NCT05066178 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (85% lower). The listed sponsor is MGH Institute of Health Professions, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which CAS Treatment for Minimally Verbal Children with Autism is the first listed.

NCT05066178 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05066178 about?

NCT05066178 is a clinical study titled "Speech Treatment for Minimally Verbal Children With ASD and CAS". Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with ...

What is the current status of trial NCT05066178?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-05-01. Estimated completion is 2026-11-30.

What conditions does trial NCT05066178 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder, Developmental Verbal Dyspraxia.

What interventions are being tested in trial NCT05066178?

The interventions under investigation include: CAS Treatment for Minimally Verbal Children with Autism (BEHAVIORAL).

Who is sponsoring clinical trial NCT05066178?

This trial is sponsored by MGH Institute of Health Professions, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05066178 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.